The LIAISON® Anti-HBc assay uses chemiluminescent immunoassay (CLIA) technology for the qualitative determination of total antibodies to Hepatitis B core Antigen (Anti-HBc) in human serum and plasma samples included specimens collected post-mortem (non-heart beating).

The assay is intended as an aid in the diagnosis of HBV infection in individuals with or without symptoms of hepatitis. It is also intended as a screening test for blood and hemocomponents donors as well as for organ, tissue and cells post-mortem donors.

The test has to be performed on the LIAISON® Analyzer family.

Number of Tests: 100/kit